Business Wire

EVERIMPACT

14.12.2022 16:50:36 CET | Business Wire | Press release

Share
Carbon Monitoring and Monetisation Start-Up Everimpact Closes €1.7M Round

Everimpact, a Climate tech start-up founded by former UN execs and headquartered at Station F (Paris), closes a €1.711M seed funding round backed by leading VCs, corporate ventures and institutions to better measure carbon emissions and allow cities and high emitters to access climate finance to fund impactful climate projects.

The round, led by Motion ventures, includes international organizations, transport companies and impact investors; EU Commission (Climate-Kic and EIT Urban Mobility), Asian Development Bank (ADB Ventures), Transport Companies' VCs and CVCs (Wilhelmsen, Transport Capital, IMC Ventures, MOL PLUS, Blue Star Group) and Impact investors (Rainmaking Impact).

While greenhouse gas emissions (GHG) have been increasingly under scrutiny in the past years, they are mainly self-reported by emitters, based on estimates and updated once a year at best.

Everimpact’s carbon Monitoring, Reporting, and Verification (MRV) platform allows cities and organisations to measure GHG emissions more accurately and in real time, thanks to satellite, ground sensors, and AI data.

Everimpact also certifies carbon emissions and sequestration data to allow cities and industries to better identify reduction opportunities and access carbon finance to fund projects with a demonstrable climate impact.

The start-up is already working with the cities of Dijon (France) with EDF and British cities - in partnership with BT - to monitor and monetise their emissions. Several other cities from the Net Zero City initiative have expressed interest since attracting funding into transport, waste and building decarbonisation is key to successfully implement City Climate contracts. In Japan, Everimpact is partnering with Hitachi Systems to monitor carbon sequestration in municipal forests.

The backing of Everimpact by maritime and supply chain leaders also involves an engineering collaboration aiming at installing its solution onboard vessels to accurately measure their emissions and get access to carbon markets to finance decarbonisation.

This will help the shipping industry accelerate its decarbonisation while complying with significant changes in its environmental regulation such as the Carbon Intensity Indicator rating kicking in 2023 and the inclusion of maritime emissions in the EU Emissions Trading Systems in the next two years.

The funding will be used to expand carbon monitoring and monetisation capabilities in cities at a global level and expand the shipping measurement solution currently trialed on a Mitsubishi Corporation Group vessel and available through an Early Adopter Program.

Mathieu Carlier, CEO and Founder at Everimpact

“Cities and high emitters have a crucial role to play to accelerate the transition to a low carbon world. Thanks to Everimpact's innovative carbon tracking system, they are now able to move away from estimates to monitor their carbon footprint in real time, identify the best opportunities to cut emissions, and access new funding for their decarbonisation projects. We’re excited to partner with leading global organisations and investors to accelerate our development.”

Nicklas Viby Fursund, General Partner of Motion Ventures said: “Bringing together those from the public and private sector with the most influence on maritime and global supply chains is unprecedented. The pairing of the engineering collaboration and strategic capital is not just a milestone for Everimpact but a proof point for a consortium approach to innovation.”

About Everimpact

Everimpact helps cities and businesses accurately measure their greenhouse gas emissions, identify opportunities to reduce emissions, and finance required investments through the carbon markets.

While most cities and businesses report GHG emissions based on estimates, Everimpact IoT software combines satellite, ground sensors, and AI data to precisely measure emissions in real-time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213005661/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye